Advertisements

ENTBD (ENTBD) Stock Quote

Detailed Quote for ENTBD
N/A N/A (N/A) Volume: 0 N/A
Today 5d 1m 3m 1y more
Last Price
N/A
Change $
N/A
Change %
N/A
Tick
N/A
Bid
N/A
Bid Size
0
Ask
N/A
Ask Size
0
Open
N/A
High
N/A
Low
N/A
Prev Close
N/A
Last Trade
N/A
Volume
0
52 Wk Hi
N/A
52 Wk Low
N/A
Market Cap
N/A
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
N/A
EPS (TTM)
N/A
PE Ratio
N/A
Exchange
NSD
News and Media for ENTBD
Sector News | Topic News
News for ENTBD
Fri, Sep 29, 2017
10:09 AM Entest BioMedical Inc. Announces 3 Million Share Zander Therapeutics, Inc. Dividend to be Paid to Shareholders - PR Newswire
Wed, Sep 13, 2017
8:00 AM Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board - PR Newswire
Wed, Jul 26, 2017
9:45 AM Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immune Suppression of IL-17a and IL-2 in Dogs With Novel NR2F6 Activators - PR Newswire
Tue, Jun 27, 2017
5:30 AM Zander Therapeutics Inc. Announces Brian Devine, Former Chairman of PETCO, to Helm its Business Advisory Board - PR Newswire
Tue, Jun 13, 2017
4:00 PM Entest BioMedical's Subsidiary Zander Therapeutics, Inc., Reports Its Series A Compounds Suppressed the Production of Multiple Cytokines Known to be Involved in Inflammation With No Toxicity In Canine Studies - PR Newswire
Wed, Jun 07, 2017
8:00 AM Entest BioMedical's Subsidiary Zander Therapeutics, Inc. Reports on Preliminary Canine Experiments Testing New Anti-Inflammatory Drug Compounds - PR Newswire
Wed, May 31, 2017
8:30 AM Entest BioMedical, Inc. Settles $841,531 of Principal Indebtedness Through the Issuance of Equity Securities - PR Newswire
Tue, May 23, 2017
10:34 AM Entest BioMedical Inc. Subsidiary Zander Therapeutics Discusses Developments in Medicinal Chemistry for Veterinary Applications of Cancer and Autoimmune Therapies Through Modulation of Checkpoint NR2F6 - PR Newswire
Wed, Apr 26, 2017
8:30 AM Entest BioMedical's Chairman Discusses its Subsidiary, Zander Therapeutics, Inc.'s Progress With Small Molecule Immunotherapies for Treating Cancer and Arthritis in Dogs - PR Newswire
Wed, Apr 19, 2017
8:00 AM Entest BioMedical's Subsidiary, Zander Therapeutics, Inc., Initiates Ex Vivo Studies on Modulating NR2F6 in Canines - PR Newswire
Thu, Mar 09, 2017
8:00 AM Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Announces Appointment of Dr. Thomas Donnelly to Serve as Senior Veterinary Advisor - PR Newswire
Wed, Feb 15, 2017
8:00 AM Entest BioMedical Inc.'s Zander Therapeutics Unit Announces Publication of Canine Cellular Immunotherapy Patent Application for Treating Cancer in Dogs - PR Newswire
Mon, Feb 06, 2017
8:30 AM Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Makes Key Additions to Management Team as the Company Prepares to Move Forward in the $63 Billion Veterinary / Pet Market Niche - PR Newswire
Tue, Jan 10, 2017
8:00 AM Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Files Patent Application on its Proprietary NR2F6 Target for the Treatment of Exercise Induced Pulmonary Hypertension Frequently Found in Thoroughbred Horses - PR Newswire
Wed, Dec 21, 2016
8:00 AM Entest BioMedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary and Future Plans for the Company Moving into 2017 - PR Newswire
More News for ENTBD >>

Tags for ENTBD

Research stocks or mutual funds related to ENTBD by keywords or tags. Find companies that have a similar focus to ENTBD. The keywords below have been associated to ENTBD by either user submission or electronic means.